Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

被引:4
|
作者
Lin, Shin-Yi [1 ,2 ]
Kuo, Ching-Hua [2 ]
Ho, Li-Ting [3 ,4 ]
Liu, Yen-Bin [3 ,4 ]
Huang, Chih-Fen [1 ,2 ]
Tang, Sung-Chun [5 ,6 ]
Jeng, Jiann-Shing [5 ,6 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Cardiovasc Ctr, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan
关键词
atrial fibrillation; edoxaban; factor Xa inhibitors; therapeutic drug monitoring; Asians; PREDICTING STROKE; PHARMACODYNAMICS; PHARMACOKINETICS; ANTICOAGULANT; WARFARIN; OUTCOMES; RISK;
D O I
10.3389/fphar.2021.736826
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations. Methods: Participants with atrial fibrillation who were undergoing edoxaban therapy were enrolled. Peak (1-4 h after edoxaban administration) and trough (24 +/- 4 h from the last edoxaban dose) blood samples were collected to measure edoxaban concentrations using ultrahigh-performance liquid chromatography with tandem mass spectrometry. The edoxaban concentrations were compared to those observed in clinical trials to define a higher- or lower-than-expected range. Multivariate logistic regression was used to analyze the risk factors associated with high or low edoxaban concentrations. Results: Eighty participants (49 men, 61.3%) were enrolled and provided 78 trough and 76 peak samples. Twenty participants (25.6%) were determined to have low trough concentrations, which was associated with higher creatinine clearance and the use of the 30 mg regimen (odds ratio [OR] and 95% confidence interval [CI], 1.06 [1.01, 1.11], p = 0.01 and 5.77 [1.34, 24.75], p = 0.02, respectively). In contrast, 21 participants (27.6%) had high peak concentrations, which was associated with an off-label overdosing regimen (OR = 4.68 [1.23, 17.70], p = 0.02). Conclusion: Our study identified factors associated with increased or decreased edoxaban exposure. The measurement of edoxaban concentration may be recommended for patients with selected characteristics.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation
    Kim, Young Dae
    Lee, Kyung Yul
    Nam, Hyo Suk
    Han, Sang Won
    Lee, Jong Yun
    Cho, Han-Jin
    Kim, Gyu Sik
    Kim, Seo Hyun
    Cha, Myoung-Jin
    Ahn, Seong Hwan
    Oh, Seung-Hun
    Lee, Kee Ook
    Jung, Yo Han
    Choi, Hye-Yeon
    Han, Sang-Don
    Lee, Hye Sun
    Nam, Chung Mo
    Kim, Eun Hye
    Lee, Ki Jeong
    Song, Dongbeom
    Park, Hui-Nam
    Heo, Ji Hoe
    YONSEI MEDICAL JOURNAL, 2015, 56 (02) : 410 - 417
  • [42] Factors Predicting Stroke Recurrence in Stroke Patients with Atrial Fibrillation
    Po, Helen L.
    Lin, Ya Ju
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2022, 16 (04) : 343 - 347
  • [43] Clinically Meaningful Change in Quality of Life and Associated Factors Among Older Patients With Atrial Fibrillation
    Abu, Hawa O.
    Saczynski, Jane S.
    Mehawej, Jordy
    Tisminetzky, Mayra
    Kiefe, Catarina I.
    Goldberg, Robert J.
    McManus, David D.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (18):
  • [44] Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation
    Satoshi Ueshima
    Daiki Hira
    Sayana Matsuda
    Rio Michihata
    Yohei Tabuchi
    Tomoya Ozawa
    Hideki Itoh
    Moritake Iguchi
    Masaharu Akao
    Takanori Aizawa
    Asami Kashiwa
    Satoshi Shizuta
    Takeru Makiyama
    Yoshihisa Nakagawa
    Minoru Horie
    Tomohiro Terada
    Toshiya Katsura
    Journal of Pharmaceutical Health Care and Sciences, 11 (1)
  • [45] Factors associated with confidence in decision making and satisfaction with risk communication among patients with atrial fibrillation
    Hedberg, Berith
    Malm, Dan
    Karlsson, Jan-Erik
    Arestedt, Kristofer
    Brostrom, Anders
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2018, 17 (05) : 446 - 455
  • [46] Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation
    Aronow, Wilbert S.
    Shamliyan, Tatyana A.
    AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (03) : E270 - E285
  • [47] Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation
    Plitt, Anna
    Giugliano, Robert P.
    FUTURE CARDIOLOGY, 2014, 10 (02) : 153 - 155
  • [48] Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
    Giugliano, Robert P.
    Ruff, Christian T.
    Wiviott, Stephen D.
    Nordio, Francesco
    Murphy, Sabina A.
    Kappelhof, Johannes A. N.
    Shi, Minggao
    Mercuri, Michele F.
    Antman, Elliott M.
    Braunwald, Eugene
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (08) : 850 - +
  • [49] Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban
    Hiramatsu, Shotaro
    Osanai, Hiroyuki
    Sakai, Yuichiro
    Sogo, Yoshiki
    Tanaka, Yuki
    Matsumoto, Hikari
    Miyamoto, Shun
    Tagahara, Kensuke
    Arai, Kenji
    Watanabe, Takashi
    Sakamoto, Yusuke
    Sakaguchi, Teruhiro
    Oguchi, Shioh
    Kanbara, Takahiro
    Nakashima, Yoshihito
    Asano, Hiroshi
    Ajioka, Masayoshi
    JOURNAL OF ARRHYTHMIA, 2024, 40 (05) : 1126 - 1130
  • [50] Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study
    Yamashita, Takeshi
    Igawa, Yoshiyuki
    Fukuzawa, Masayuki
    Hayashi, Takuya
    Hennig, Stefanie
    Okumura, Ken
    THROMBOSIS AND HAEMOSTASIS, 2024, 124 (09) : 874 - 882